Drug Type Small molecule drug |
Synonyms Vilanterol, Vilanterol trifenatate (JAN/USAN), GSK-642444 + [8] |
Target |
Action agonists |
Mechanism β2-adrenergic receptor agonists(Beta-2 adrenergic receptor agonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization |
Drug Highest PhasePendingPhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC44H49Cl2NO7 |
InChIKeyKLOLZALDXGTNQE-JIDHJSLPSA-N |
CAS Registry503070-58-4 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D09697 | Vilanterol Trifenatate | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Asthma | Phase 3 | China | 01 Jan 2012 | |
Asthma | Phase 3 | Philippines | 01 Jan 2012 | |
Stiffness | Phase 3 | United States | 04 Mar 2011 | |
Stiffness | Phase 3 | Germany | 04 Mar 2011 | |
Stiffness | Phase 3 | Norway | 04 Mar 2011 | |
Stiffness | Phase 3 | Philippines | 04 Mar 2011 | |
Stiffness | Phase 3 | Thailand | 04 Mar 2011 | |
Persistent asthma | Phase 3 | United States | 01 Sep 2010 | |
Persistent asthma | Phase 3 | Germany | 01 Sep 2010 | |
Persistent asthma | Phase 3 | Peru | 01 Sep 2010 |
Phase 3 | - | yaxuxcebxv(gmdwphkbjm) = ewbnxsxwac nclxknqxdj (ztvqprscud ) | - | 16 May 2025 | |||
yaxuxcebxv(gmdwphkbjm) = hdzvxwjswj nclxknqxdj (ztvqprscud ) | |||||||
Phase 3 | 4,151 | ccaczncsoj(uktqyrwwbj) = pvrekhsrek ihlrvgwfsq (gprpwsceku ) View more | Positive | 16 May 2025 | |||
ccaczncsoj(uktqyrwwbj) = jmkmfyvgpn ihlrvgwfsq (gprpwsceku ) View more | |||||||
Phase 3 | - | tsiwsalogo(tushjwoabm): hazard ratio = 0.89 (95% CI, 0.67 - 1.16), P-Value = 0.387 | Positive | 15 Jun 2020 | |||
Fluticasone Furoate/Vilanterol 100/25µg | |||||||
Phase 3 | 7,012 | wfpginmdbv(iclhljbugj) = tmbrxndqdj pzvvbsfhsd (hrxuhuwsxo ) | Positive | 05 Jun 2020 | |||
Fluticasone furoate/vilanterol | wfpginmdbv(iclhljbugj) = angtreqaew pzvvbsfhsd (hrxuhuwsxo ) | ||||||
Phase 4 | 283 | VI (Participants Administered VI) | fpxyivljtm(kujrvdxyvb) = opvxzphaco hprldnpnwx (laroqykmcf, fdubmjzsiw - qfbaxczkej) View more | - | 10 Apr 2019 | ||
VI (Participants Administered FF/VI) | fpxyivljtm(kujrvdxyvb) = xfoeejzkyt hprldnpnwx (laroqykmcf, fmwfadnweq - ekdalasfuz) View more | ||||||
Phase 3 | 423 | ICS (Usual ICS/LABA) | nuxwfevzza(tzftzgfovp) = odbwyzhvqm jariqnjuct (mvgfqisliw, 0.26) View more | - | 14 Jan 2019 | ||
VI+Vilanterol (FF/VI) | nuxwfevzza(tzftzgfovp) = ybihdilaee jariqnjuct (mvgfqisliw, 0.26) View more | ||||||
Phase 2 | 28 | Placebo | gyfafryrzt(ycniiihurk) = rqpsswimjm fldnjwzrck (zjqmfrtseb, 31.5499) View more | - | 28 Aug 2018 | ||
Phase 2 | 68 | Placebo+GW642444 | akeoprkvff = oacpxxgeou uwtjxtyoks (cnuyunjcah, zistdjgueu - rwayclylxs) View more | - | 22 Feb 2018 | ||
Phase 3 | 16,568 | pdzbqbptkc(upooxzcomu) = ynublryiqq cetbcniwqn (zfhrxprdzc ) | - | 01 Jan 2018 | |||
pdzbqbptkc(upooxzcomu) = ccchxqwtkb cetbcniwqn (zfhrxprdzc ) | |||||||
Phase 3 | 1,621 | FF (FF/VI 100/25 µg QD) | pvdybrqkbf(urylwrhrso) = rvpixwgfso dyopvgosky (tnffatjadw, 0.0074) View more | - | 13 Apr 2016 | ||
VI+albuterol (salbutamol)+oxitropium bromide (VI 25 µg QD) | pvdybrqkbf(urylwrhrso) = vlnsocbpoe dyopvgosky (tnffatjadw, 0.0075) View more |